Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro

Table 1

Statistics on patients’ clinical data, classical prognostic factors, and PGIS expression ().

Parameter	(193)	PGIS expression
		IRS: 0–2	%	IRS: 3–12	%
		Patients ()		Patients ()
Median age, years		54
Age ≷ median		83/110				0.127
<56 years	83	66	79.5	17	20.5%	>0.05
>56 years	110	84	76.4	54	23.6%
Menopausal status
Pre/post/?	56	37/100/56				0.715
Premenopausal	37	30	81.1	7	18.9%	>0.05
Postmenopausal	100	81	81.0	19	19.0%
Tumor size
T1/T2/T3/T4/?	4	29/102/45/8/9				0.0068
<2 cm	45	39	86.7	6	13.3%	>0.05
>2 cm	144	109	75.7	35	24.3%
Nodal status
N0/N1/N2/N3/?	3	80/92/13/5/3				<0.0001
N0 node negative	80	63	78.8	17	21.3%	>0.05
N1–N3 node positive	110	85	77.3	25	22.7%
Grading
G1/G2/G3/?	4	8/122/59/4				0.0402
G1 & G2	130	108	83.1	22	16.9%	>0.05
G3	59	39	66.1	20	33.9%
ER/PR
++//+−&−+//−−//?		96/30/57/10				0.230
Pos/pos	96	78	81.2	18	18.8%	>0.05
Pos/neg or neg/pos	30	20	66.6	10	33.3%
Neg/neg	57	43	75.4	14	24.6%

PGIS = prostacyclinsynthase; IRS = immunoreactive score; IRS 0–2 = low PGIS expression; IRS 3–12 = high PGIS expression; = number; cm = centimeter; ER = estrogen receptor; PR = progesterone receptor; pos = positive; neg = negative.
value for overall survival (log-rank test).
P value for expression of PGIS ( test).